Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Trial Profile

Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Influenza virus vaccine (NasoVAX) (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Sponsors Altimmune
  • Most Recent Events

    • 10 Aug 2017 According to an Altimmune media release, the company is on track to initiate this study in the third quarter of 2017 with initial data expected in first quarter of 2018.
    • 03 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top